MeCP2 level is associated with hepatocellular carcinoma development in chronic hepatitis B patients under antiviral therapy.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  International Journal of Clinical and Experimental Pathology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 31938231PMCID PMC6958145
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy

  2017cited by this paper
• Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.

  2016cited by this paper
• Therapeutic Strategies in HCC: Radiation Modalities

  2016cited by this paper
• Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

  2015cited by this paper
• Impact of age on the survival of patients with liver cancer: an analysis of 27,255 patients in the SEER database

  2015cited by this paper
• Effect of Tumor Size on Cancer-Specific Survival in Small Hepatocellular Carcinoma.

  2015cited by this paper
• Validation of hepatitis B virus–related hepatocellular carcinoma prediction models in the era of antiviral therapy

  2015cited by this paper
• Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers

  2015cited by this paper
• EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.

  2015cited by this paper
• Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.

  2014cited by this paper
• Factors affecting screening for hepatocellular carcinoma.

  2014cited by this paper
• The Pathogenesis of Hepatocellular Carcinoma

  2014cited by this paper
• DNA Methylation and Cancer Diagnosis

  2013cited by this paper
• DNA Methylation Biomarkers for Noninvasive Diagnosis of Colorectal Cancer

  2013cited by this paper
• Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.

  2013cited by this paper
• Expression of DNA Methyltransferases in Breast Cancer Patients and to Analyze the Effect of Natural Compounds on DNA Methyltransferases and Associated Proteins

  2013cited by this paper
• Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

  2013cited by this paper
• Co-Localization of the Oncogenic Transcription Factor MYCN and the DNA Methyl Binding Protein MeCP2 at Genomic Sites in Neuroblastoma

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• L1 retrotransposition in neurons is modulated by MeCP2

  2010cited by this paper
• Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.

  2009cited by this paper
• Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B.

  2009cited by this paper
• Methyl-CpG Binding Domain Proteins and Their Involvement in the Regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 Gene Promoters

  2007cited by this paper
• Mammalian DNA methyltransferases.

  2006cited by this paper
• Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

  2006cited by this paper
• Pathogenesis of hepatocellular carcinoma.

  2005cited by this paper
• Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.

  2003cited by this paper
• Methyl‐CpG binding proteins identify novel sites of epigenetic inactivation in human cancer

  2003cited by this paper
• Long‐term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B

  2002cited by this paper
• Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis

  2001cited by this paper
• Chronic hepatitis B virus infection in Asian countries

  2000cited by this paper
• 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers

  1995cited by this paper
• Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.

  1995cited by this paper
• Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA.

  1992cited by this paper
• Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA.

  1992cited by this paper
• Receiver operating characteristic (ROC) methodology: the state of the art.

  1989cited by this paper

• circFOXM1 contributes to sorafenib resistance of hepatocellular carcinoma cells by regulating MECP2 via miR-1324

  2021cites this paper